[Comment] Progress in Alzheimer's disease: The Lancet Series

The past two decades have seen major advances in Alzheimer's disease research and clinical care, catalysed by the development of CSF and blood biomarkers and PET imaging that reliably detect amyloid β plaques and tau neurofibrillary tangles, the core neuropathological features of the disease. The availability of biomarkers revolutionised the design of longitudinal clinical studies and drug trials, culminating in the development of a new class of therapeutics—anti-amyloid β monoclonal antibodies—that effectively clear amyloid β plaques and modestly slow clinical decline.